Short answer
UTAH MEDICAL PRODUCTS INC (UTMD) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $10M (down 1.9% year over year) with net income of $3M.
Q3 2025 key financials · XBRL
- Revenue
- $10M
- −1.9% YoY · −1.4% QoQ
- Net income
- $3M
- −26.2% YoY · −13.7% QoQ
- Operating margin
- 26.6%
- Gross margin
- 57.1%
- EPS (diluted)
- $0.82
- −20.4% YoY · −12.8% QoQ
Source: XBRL data from the UTAH MEDICAL PRODUCTS INC (UTMD) Q3 2025 10-Q on SEC EDGAR. USD.
UTAH MEDICAL PRODUCTS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $9.812M, down 1.9% YoY from $10.005M
- Operating margin 26.6% vs 33.4%; net income margin 26.8% vs 35.6%
- Best category Neonatal sales $2.176M, up 27%; worst Blood Pressure and Accessories $1.643M, down 23%
- Cash deployment included $3.006M dividends and $7.361M share repurchases through 9M
- 2025 sales outlook reduced to approximately 7% below 2024 from prior 5% projection; distributor cancellations and weaker OUS conditions cited
Risk Factors
- No risk-factors section provided; supplied text covers share repurchases and exhibits
- Repurchase activity: 131,484 shares bought through November 10, 2025 at average $56.21 per share
- Capital-allocation risk: ongoing open-market repurchases lack board-established expiration date or maximum dollar limit
- Liquidity risk: excess cash deployed for repurchases, potentially reducing funds available for operations
- Nasdaq compliance risk: repurchases constrained to avoid terminating Nasdaq Global Market listing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other UTAH MEDICAL PRODUCTS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.